Fig. 1: Timeline of main clinical events of ADA SCID P21, having developed T-ALL after γRV-GT.
From: A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID
In the top green arrow, the main clinical events are reported as months of life, in the second blue arrow as months post-GT, in the third light blue arrow as months post-T-ALL onset and in the bottom salmon arrow as months post-allogeneic HSCT. Data are updated as of June 2023. The dashed lines between the arrows connect the same clinical events on different timelines. *Measles from wild-type virus. CMV: cytomegalovirus; ADA SCID: Adenosine Deaminase-Deficient Severe Combined Immune Deficiency; PEG-ADA: Polyethylene glycol-modified adenosine deaminase. AHA: Autoimmune Hemolytic Anemia. γRV-GT: Gamma-retroviral-Gene Therapy T-ALL: T-cell acute lymphoblastic leukemia Ia & Ib: Induction therapy a & b; HR1, 2, 3: High-Risk Blocks 1, 2, 3 MRD: Minimal Residual Disease HSCT: Haematopoietic Stem Cell Transplantation DLI: Donor Lymphocyte Infusion F-U: Follow-Up.
